GSK3β is a negative regulator of platelet function and thrombosis

Blood

Volumn 111, Issue 7, 2008, Pages 3522-3530

  Li, Dongjun ^a   August, Shelley ^a   Woulfe, Donna S ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Rm 408 College Bldg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; FERRIC CHLORIDE; FIBRINOGEN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SERINE; THROMBIN; ENZYME INHIBITOR; FERRIC ION; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; TOXIC SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; CAROTID ARTERY INJURY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SECRETORY GRANULE; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; ETHNOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; CAROTID ARTERY INJURIES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FERRIC COMPOUNDS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, KNOCKOUT; NOXAE; PHOSPHORYLATION; PLATELET AGGREGATION; PROTO-ONCOGENE PROTEINS C-AKT; THROMBOSIS;

EID: 43549100273     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-111518     Document Type: Article

References (61)

1. Dunkley S, Arthur JF, Evans S, Gardiner EE, Shen Y, Andrews RK. A familial platelet function disorder associated with abnormal signalling through the glycoprotein VI pathway. Br J Haematol. 2007;137:569-577.
2. Kojima H, Moroi M, Jung SM, et al. Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost. 2006;4:2433-2442.
3. Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA. 2003; 100:1978-1983.
4. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the plateletADP receptor targeted by antithrombotic drugs. Nature. 2001 ;409:202-207.
5. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet "primary secretion defect" are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vase Biol. 2000;20:E101-106.
6. Gabbeta J, Yang X, Kowalska MA, Sun L, Dha-nasekaran N, Rao AK. Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA. 1997;94:8750-8755.
7. Jin Y Dietz HC, Montgomery RA, et al. Glanz-mann thrombasthenia: cooperation between sequence variants in cis during splice site selection. J Clin Invest. 1996;98:1745-1754.
8. Ludlow LB, Schick BP, Budarf ML, et al. Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibbeta promoter resulting in the Bernard-Soulier syndrome. J Biol Chem. 1996;271:22076-22080.
9. Grimaldi CM, Chen F, Scudder LE, Coller BS, French DL. A Cys374Tyr homozygous mutation of platelet glycoprotein Ilia (beta3) in a Chinese patient with Glanzmann's thrombasthenia. Blood. 1996:88:1666-1675.
10. Li C, Martin SE, Roth GJ. The genetic defect in two well-studied cases of Bernard-Soulier syndrome: a point mutation in the fifth leucine-rich repeat of platelet glycoprotein lb alpha. Blood. 1995;86:3805-3814.
11. Nurden P, Savi P, Heilmann E, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets: its influence on glycoprotein Ilb-IIla complex function. J Clin Invest. 1995;95:1612-1622.
12. Leon G, Hechler B, Freund M, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999;104:1731-1737.
13. Andre P, Delaney SM, LaRocca T, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003;112:398-406.
14. Zhang J, Zhang J. Shattil SJ. Cunningham MC, Rittenhouse SE. Phosphoinositide 3-kinase gamma and p85/phosphoinositide 3-kinase in platelets: relative activation by thrombin receptor or beta-phorbol myristate acetate and roles in promoting the ligand-binding function of alphallb-betaS integrin. J Biol Chem. 1996;271:6265-6272.
15. Kim S, Jin J, Kunapuli SP. Relative contribution of G-protein-coupled pathways to protease-acti-vated receptor-mediated Akt phosphorylation in platelets. Blood. 2006;107:947-954.
16. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. Faseb J. 2001;15:2019-2021.
17. Lian L, Wang Y, Draznin J, et al. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood. 2005;106:110-117.
18. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005;11:507-514.
19. Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood. 2004;104:1703-1710.
20. Marjanovic JA, Li Z, Stojanovic A, Du X. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J Biol Ghem. 2005; 280:37430-37438.
21. Morrell CN, Matsushita K, Chiles K, et al. Regulation of platelet granule exocytosis by S-nitrosyla-tion. Proc Natl Acad Sci USA. 2005;102:3782-3787.
22. Zhang W, Colman RW. Thrombin regulates intracellular cAMP concentration in human platelets through phosphorylation/activation of PDE3A. Blood. 2007;110:1475-1482.
23. Barry FA, Graham GJ, Fry MJ, Gibbins JM. Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? FEBS Lett. 2003;553:173-178.
24. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789.
25. McManus EJ, Sakamoto K, Armit LJ, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. Embo J. 2005;24:1571-1583.
26. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-Salpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003;423: 435-439.
27. Martin M, Rehani K, Jope RS, Michalek SM. Tolllike receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005;6:777-784.
28. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation: characterization of dominant-negative mutant of PKB. J Biol Chem. 1998;273:13150-13156.
29. Wang Q, Zhou Y, Wang X, Evers BM. Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene. 2006;25:43-50.
30. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21 Cip1 degradation. J Biol Ghem. 2002; 277:9684-9689.
31. Pap M, Gooper GM. Role of translation initiation factor 2B in control of cell survival by the phos- phatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway. Mol Cell Biol. 2002;22:578-586.
32. Liu S, Yu S, Hasegawa Y, et al. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem. 2004;279:51075-51081.
33. Woulfe D, Jiang H, Morgans A, Monks R, Birn-baum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest. 2004;113:441-450.
34. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kap-paB activation. Nature. 2000;406:86-90.
35. O'Brien WT, Harper AD, Jove F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci. 2004;24:6791-6798.
36. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birn- baum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001; 276:38349-38352.
37. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001:292:1728-1731.
38. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 2003;17:1352-1365.
39. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104:1606-1615.
40. Liu F, Liang Z, Shi J, et al. PKAmodulates GSK- 3beta-and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett. 2006;580:6269-6274.
41. Lin YT, Cheng JT, Liang LC, Ko CY, Lo YK, Lu PJ. The binding and phosphorylation of Thr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3beta. J Neurochem. 2007;103:802-813.
42. Cho J, Johnson G. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neuro- chem. 2004;88:349-358.
43. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202:271-281.
44. Pozgajova M, Sachs UJ, Hein L, Nieswandt B. Reduced thrombus stability in mice lacking the alpha2A-adrenergic receptor. Blood. 2006;108: 510-514.
45. Trivedi CM, Luo Y, Yin Z. et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med. 2007;13:324-331.
46. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-cate-nin, tau hyperphosphorylation and neurodegen-eration in GSK-3beta conditional transgenic mice. Embo J. 2001;20:27-39.
47. Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Gohen P. Glycogen synthase from rabbit skeletal muscle: amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur J Biochem. 1980;107:529-537.
48. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32:577- 595.
49. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3:1141-1154.
50. Berry S, Dawicki DD, Agarwal KC, SteinerM. The role of microtubules in platelet secretory release. Biochim Biophys Acta. 1989;1012:46-56.
51. Menche D, Israel A, Karpatkin S. Platelets and microtubules: effect of colchicine and D20 on platelet aggregation and release induced by calcium ionophoreA23187. J Clin Invest. 1980;66: 284-291.
52. White JG, Rao GH. Effects of a microtubule stabilizing agent on the response of platelets to vincristine. Blood. 1982;60:474-483.
53. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med. 2006;12:89-98.
54. Reading HW, Rosie R. Effects of lithium and halo-peridol on blood platelet function [proceedings]. Biochem SocTrans. 1979;7:933-935.
55. Imandt L, Genders T, Wessels H, Haanen C. The effect of lithium on platelet aggregation and platelet release reaction. Thromb Res. 1977; 11:297-308.
56. Bhat RV, Budd Haeberlein SL Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem. 2004;89:1313-1317.
57. Kerkela R, Woulfe K, Force T. Glycogen synthase kinase-3beta-actively inhibiting hypertrophy. Trends Cardiovasc Med. 2007;17:91-96.
58. Dugo L, Collin M, Allen DA, et al. Inhibiting glycogen synthase kinase 3beta in sepsis. Novartis Found Symp. 2007;280:128-142; discussion 142-126, 160-124.
59. Perrier A, Martin P, Favre H, Muller A, Urban P, Chevrolet J. Very severe self-poisoning lithium carbonate intoxication causing a myocardial infarction. Chest. 1991;100:863-865.
60. Warick L. Lithium poisoning: report of a case with neurologic, cardiac and hepatic sequelae. West J Med. 1979;130:259-263.
61. Pratt LA, Ford DE, Crum RM. Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore EGA follow-up. Circulation. 1996;94:3123-3129.